Newsroom
Saniona Icon blue
Latest News
July 26, 2021
PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S.
July 14, 2021
PRESS RELEASE July 14 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a non-dilutive term loan agreement for SEK 87 million ( $10 million ) with Formue Nord Fokus A/S.
June 30, 2021
PRESS RELEASE June 30 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patient in a P hase 1 clinical trial of SAN711, a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine.
If you have any questions regarding Saniona's media communication, feel free to contact us at any time.
trista morrison
Trista Morrison, Chief Communications Officer Phone: +1 781.810.9227 Email: trista.morrison@saniona.com